L&G Pharma Breakthrough UCITS ETF (LON: BIGT)
London
· Delayed Price · Currency is GBP · Price in GBX811.20
+4.75 (0.59%)
Jan 7, 2025, 3:09 PM BST
-0.49% (1Y)
| Assets | 17.93M |
| Expense Ratio | 0.49% |
| PE Ratio | 17.11 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -0.49% |
| Volume | 10 |
| Open | 813.40 |
| Previous Close | 806.45 |
| Day's Range | 811.20 - 813.40 |
| 52-Week Low | 721.90 |
| 52-Week High | 865.20 |
| Beta | 0.59 |
| Holdings | 39 |
| Inception Date | Jan 23, 2018 |
About BIGT
BIOT.L was created on 2018-01-23 by L&G . The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 17.83m in AUM and 38 holdings. The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Asset Class Equity
Category Health Care
Stock Exchange London Stock Exchange
Ticker Symbol BIGT
Provider L&G
Index Tracked Solactive Pharma Breakthrough Value Index
Performance
BIGT had a total return of -0.49% in the past year. Since the fund's inception, the average annual return has been -2.79%, including dividends.
Top 10 Holdings
34.89% of assets| Name | Symbol | Weight |
|---|---|---|
| Pharma Mar, S.A. | PHM | 5.40% |
| Xeris Biopharma Holdings, Inc. | XERS | 4.13% |
| Bristol-Myers Squibb Company | BMY | 3.34% |
| argenx SE | ARGX | 3.30% |
| Jazz Pharmaceuticals plc | JAZZ | 3.23% |
| Ligand Pharmaceuticals Incorporated | LGND | 3.14% |
| Supernus Pharmaceuticals, Inc. | SUPN | 3.14% |
| Catalyst Pharmaceuticals, Inc. | CPRX | 3.12% |
| InnoCare Pharma Limited | 9969 | 3.12% |
| United Therapeutics Corporation | UTHR | 2.96% |